Abstracts Archive - Page 457 of 2605 - ACR Meeting Abstracts

Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
COMFORT ANIM-KORANTENG¹, YONG EUN², Okeoghene Akpoigbe² and AMANDA SAMMUT², ¹Harlem Hospital Center, New York, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
Abstract Number: 2028 • ACR Convergence 2023
Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact
Kevin Yip¹, Suellen Lyne², Vasilis Vasiliou³, David Katz⁴, Pamela Richards⁵, Joanna Tieu⁶, Rachel Black⁷, Susan Bridgewater⁸, Dorcas Beaton⁹, lara maxwell¹⁰, Jo Robson⁸, Sarah Mackie¹¹, Catherine Hill⁶ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²The Queen Elizabeth Hospital, Adelaide, Australia, ³Royal Holloway, University of London, London, United Kingdom, ⁴Sparrow Pharmaceuticals, Portland, OR, ⁵NA, Bristol, United Kingdom, ⁶The Queen Elizabeth Hospital, Woodville, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸University of the West of England, Bristol, United Kingdom, ⁹Institute for Work & Health, Toronto, ON, Canada, ¹⁰University of Ottawa, Ottawa, ON, Canada, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Healthcare research has historically been medically oriented, less focused on the patients' perspective that research shows can improve the quality of care. OMERACT advocates…
Abstract Number: 2001 • ACR Convergence 2023
Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis
Guy Katz¹, Aubree McMahon¹, Grace McMahon¹, Isha Jha¹, Marcy Bolster², Ana Fernandes¹, Zachary Wallace³, Cory Perugino¹, John Stone⁴ and Yasmin Hernandez-Barco¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Concord, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Metabolic bone disease (MBD), including osteopenia and osteoporosis, is common in patients with inflammatory disorders, due to disease factors and glucocorticoid (GC) use, and…
Abstract Number: 1938 • ACR Convergence 2023
Cranial Nerve Manifestations in Sarcoidosis Associated with Lymphoma, Non-facial Paralysis, and Other Neurologic Disorders
Mary Salim, Emily Kokush, Evelyne Kalyoussef, Eugenio Capitle and Reena Khianey, Rutgers New Jersey Medical School, Newark, NJ
Background/Purpose: Sarcoidosis is a systemic granulomatous inflammatory disease that affects multiple organ systems including the including the lungs, skin, skeletal, and nervous system. Cranial neuropathies…
Abstract Number: 2068 • ACR Convergence 2023
Integration of Basic Science into Virtual Patient Cases to Enhance Clinical Reasoning Skills
Karl Rombo¹, Alexander Borg¹ and Ioannis Parodis², ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Digital education, also known as e-learning, comprises several different learning modalities e.g. virtual patient (VP) simulations. VPs have been proposed to be an effective…
Abstract Number: 2046 • ACR Convergence 2023
Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic
Elizabeth Murray¹, Melissa Argraves¹, Alysha Taxter², Kelly Wise³, Paul Jensen⁴, Alana Goldstein-Leever¹, Bethanne Thomas¹, Alexa Scott¹, Jonnie Lee Hughes¹, James Gallup¹, Diana Sumano Vicente¹, Stacy Ardoin¹ and Vidya Sivaraman¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's, Columbus, OH, ³Nationwide Children's Hospital, Hilliard, OH, ⁴Intermountain Southwest Rheumatology Associates, St. George, UT
Background/Purpose: Many pediatric patients are inadequately prepared for the transition from pediatric to adult subspecialty healthcare, and patients who fail to transition successfully are more…
Abstract Number: 2062 • ACR Convergence 2023
A Mental Health Workshop for Pediatric Rheumatology Fellows
Caitlan Pinotti¹, Alison Manning², Suzanne Edison³ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Lifespan, East Providence, RI, ³Cure JM Foundation, Seattle, WA
Background/Purpose: Many children with a rheumatic disease have concurrent mental and behavioral health challenges, but only ~40% of these symptoms are brought to medical attention.…
Abstract Number: 2069 • ACR Convergence 2023
Navigating the Residency-to-Fellowship Transition in Rheumatology
Lilian Otalora Rojas¹ and Gurjit S Kaeley², ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Transitioning from residency to fellowship is a significant milestone in a medical professional's career. Physicians acquire foundational knowledge and skills during residency, while fellowship…
Abstract Number: 2059 • ACR Convergence 2023
Management of Iatrogenic, Recombinant Interleukin-1 Receptor Antagonist-type Amyloidosis on NOMID in Patients on Anakinra
Sara Alehashemi¹, Anvitha Metpally², Surendra Dasari³, Kat Uss², Londa Hathaway⁴, Douglas B. Kuhns⁵, Danielle Fink⁵, Chyi-Chia Richard Lee⁶, Leslie A Castelo-Soccio⁴, Edward W. Cowen⁴, Samih H. Nasr⁷, Ellen McPhail⁷ and Raphaela Goldbach-Mansky⁸, ¹NIH/NIAID/TADS, Clarksville, MD, ²NIAID, NIH, Bethesda, MD, ³Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁴NIAMS, NIH, Bethesda, MD, ⁵Frederick National Laboratory for Cancer Research, Bethesda, MD, ⁶NCI, NIH, Bethesda, MD, ⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁸NIH/NIAID, Potomac, MD
Background/Purpose: Patients with Neonatal-Onset Multisystem Inflammatory Disease (NOMID) often require long-term high-dose treatment with anakinra at 5-8 mg/kg daily subcutaneous injections to control CNS inflammation…
Abstract Number: 2076 • ACR Convergence 2023
Piloting a Rheumatology and Sports Medicine Case-Based Collaborative Learning Curriculum for Medical Students
M. Dave Dimachkie¹, Brittany Bettendorf² and Marion Sanders¹, ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²University of Iowa, Iowa City, IA
Background/Purpose: Case-based collaborative learning (CBCL) is an interactive teaching method that integrates cases with key concepts. CBCL is recognized as a means for knowledge improvement…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: 2061 • ACR Convergence 2023
Evaluation of a Tool to Enhance Training of the Physical Examination of the Temporomandibular Joint (TM Joint) in Juvenile Idiopathic Arthritis (JIA)
Tova Ronis¹, Nancy Pan², Rebecca Sadun³, Melissa Lerman⁴, Cory Resnick⁵, James Bost⁶, Peter Stoustrup⁷, Marinka Twilt⁸ and for the CARRA TMJ Arthritis Workgroup⁹, ¹Children's National Hospital, Chevy Chase, MD, ²Hospital for Special Surgery, New York, NY, ³Duke University, Durham, NC, ⁴Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Harvard Medical School, Boston, MA, ⁶Children's Health Center, Children's National Medical Center, Washington, DC, ⁷Aarhus University, Aarhus, Denmark, ⁸Alberta Children's Hospital, Calgary, AB, Canada, ⁹Childhood Arthritis and Rheumatology Research Alliance, Washington, DC
Background/Purpose: Arthritis of the TM joint is a frequent finding in patients with JIA, potentially leading to dentofacial deformities, pain, and lower quality of life.1…
Abstract Number: 2065 • ACR Convergence 2023
Exploring the Power of Ultrasound in Rheumatology: Insights from Young Rheumatologists in Mexico
Mario R. Garcia-Pompermayer¹, Sarah G. Ayton², Karina Silva Luna³ and Mario Alberto Garza Elizondo³, ¹Hospital San Jose, TecSalud, Tecnologico de Monterrey, Monterrey, Mexico, ²Mailman School of Public Health, Columbia University, New York, NY, ³Hospital Zambrano-Hellion, TecSalud, Tecnologico de Monterrey, Monterrey, Mexico
Background/Purpose: Musculoskeletal ultrasound (MSUS) is a valuable tool in Rheumatology as it is non-invasive, cost-effective, and useful in regular clinical practice. However, its adoption has…
Abstract Number: 1939 • ACR Convergence 2023
Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity
Emily Kokush, Mary Salim, Eugenio Capitle, Reena Khianey and Evelyne Kalyoussef, Rutgers New Jersey Medical School, Newark, NJ
Background/Purpose: Sarcoidosis is a systemic granulomatous inflammatory disease that can involve multiple organ systems. Rarely, sarcoidosis can involve the upper respiratory tract including the sinonasal…
Abstract Number: 0314 • ACR Convergence 2023
Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Leonard Kapural¹, Stephen D. Collins², Eric Grigsby³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Center for Clinical Research, Winston-Salem, NC, ²Xalud Therapeutics, Inc., Chicago, IL, ³Neurovations Clinical Research, Napa, CA, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].